Loading...
CCCC logo

C4 Therapeutics, Inc.NasdaqGS:CCCC Stock Report

Market Cap US$384.5m
Share Price
US$3.74
US$11.57
67.7% undervalued intrinsic discount
1Y196.8%
7D14.0%
1D
Portfolio Value
​
View

C4 Therapeutics, Inc.

NasdaqGS:CCCC Stock Report

Market Cap: US$384.5m

C4 Therapeutics (CCCC) Stock Overview

A clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. More details

CCCC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 77.48% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months compared to the US market


CCCC Community Fair Values

Create Narrative

See what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

C4 Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for C4 Therapeutics
Historical stock prices
Current Share PriceUS$3.74
52 Week HighUS$3.97
52 Week LowUS$1.21
Beta2.78
1 Month Change32.16%
3 Month Change34.53%
1 Year Change196.83%
3 Year Change10.32%
5 Year Change-90.16%
Change since IPO-85.33%

Recent News & Updates

Analysis Article • May 15

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its quarterly results, which were ahead of...

Recent updates

Analysis Article • May 15

C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its quarterly results, which were ahead of...
Seeking Alpha • Mar 10

C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact

Summary C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. CCCC's lead asset, cemsidomide, advanced into a Phase 2 registrational trial for relapsed/refractory multiple myeloma, targeting a large, growing TAM. Cash position strengthened to $297.1M, extending operational runway through 2028 and supporting continued pipeline investment. Valuation remains highly discounted (EV/sales 1.66x), but future success hinges on cemsidomide trial outcomes and regulatory milestones. Read the full article on Seeking Alpha
Analysis Article • Dec 17

Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price

You may think that with a price-to-sales (or "P/S") ratio of 7.3x C4 Therapeutics, Inc. ( NASDAQ:CCCC ) is a stock...
Analysis Article • Sep 05

C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33%

Despite an already strong run, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have been powering on, with a gain of 33...
Analysis Article • Jul 11

C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares have continued their recent momentum with a 27% gain in the last month...
Analysis Article • Jun 20

We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Apr 18

Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%

Unfortunately for some shareholders, the C4 Therapeutics, Inc. ( NASDAQ:CCCC ) share price has dived 40% in the last...
Seeking Alpha • Mar 10

C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here

Summary C4 Therapeutics' pipeline, including cemsidomide and CFT1946, shows early promise but faces significant safety concerns and long timelines for definitive data readouts. Financially, CCCC has sufficient cash to fund operations into 2027, reducing immediate dilution risk, but high cash burn remains a concern. Market valuation has dropped significantly, aligning more closely with their early-stage clinical status, reducing overvaluation risk. Despite potential in protein degraders, the current "Hold" sentiment is maintained due to early-stage data and lack of near-term catalysts. Read the full article on Seeking Alpha
Analysis Article • Mar 04

C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares are down a considerable 31% in the...
Analysis Article • Nov 15

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders won't be pleased to see that the share price has had a very rough...
Seeking Alpha • Nov 06

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Summary C4 Therapeutics has a promising pipeline, including cemsidomide for blood cancer and CFT1946 for solid tumors, but definitive data is still far off. Financially stable with $59.6M in cash and $196M in marketable securities, CCCC has a cash runway of 11-12 quarters, funding operations through 2025. Strengths include controlled costs and no imminent dilution risk, but the long wait for significant data readouts poses a risk for investors. Maintain a "Hold" rating; worth watching for patient, risk-tolerant investors, but not advisable to jump in headfirst just yet. Read the full article on Seeking Alpha
Analysis Article • Oct 02

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, C4 Therapeutics...
Analysis Article • Aug 09

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Analysis Article • Aug 03

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Those holding C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shares would be relieved that the share price has rebounded 41% in...
Analysis Article • May 12

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...
Seeking Alpha • Mar 01

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Summary C4 Therapeutics is developing targeted protein degraders for the treatment of various diseases, including cancer. The company's TORPEDO platform allows for the design of molecules that can break down disease-causing proteins. C4 Therapeutics has a partnership with Merck and is currently in Phase 1 clinical trials for its drug candidates. The company's current valuation appears high compared to sector peers, leading to a "hold" rating. Read the full article on Seeking Alpha
Analysis Article • Feb 29

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Shareholders in C4 Therapeutics, Inc. ( NASDAQ:CCCC ) may be thrilled to learn that the analysts have just delivered a...
Analysis Article • Feb 24

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

It's been a pretty great week for C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders, with its shares surging 13% to...
Analysis Article • Nov 03

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

C4 Therapeutics, Inc. ( NASDAQ:CCCC ) shareholders will have a reason to smile today, with the analysts making...

Shareholder Returns

CCCCUS BiotechsUS Market
7D14.0%1.0%1.3%
1Y196.8%34.2%27.7%

Return vs Industry: CCCC exceeded the US Biotechs industry which returned 33% over the past year.

Return vs Market: CCCC exceeded the US Market which returned 26.4% over the past year.

Price Volatility

Is CCCC's price volatile compared to industry and market?
CCCC volatility
CCCC Average Weekly Movement14.1%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: CCCC's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CCCC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015104Andrew Hirschwww.c4therapeutics.com

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration.

C4 Therapeutics, Inc. Fundamentals Summary

How do C4 Therapeutics's earnings and revenue compare to its market cap?
CCCC fundamental statistics
Market capUS$384.53m
Earnings (TTM)-US$103.80m
Revenue (TTM)US$34.86m
11.8x
P/S Ratio
-4.0x
P/E Ratio

Is CCCC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CCCC income statement (TTM)
RevenueUS$34.86m
Cost of RevenueUS$8.98m
Gross ProfitUS$25.88m
Other ExpensesUS$129.69m
Earnings-US$103.80m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.94
Gross Margin74.25%
Net Profit Margin-297.76%
Debt/Equity Ratio0%

How did CCCC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/27 12:46
End of Day Share Price 2026/05/27 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

C4 Therapeutics, Inc. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Chi Meng FongBofA Global Research
Leah Rush CannBrookline Capital Markets